214 related articles for article (PubMed ID: 33033255)
1. Structural characterization of the ICOS/ICOS-L immune complex reveals high molecular mimicry by therapeutic antibodies.
Rujas E; Cui H; Sicard T; Semesi A; Julien JP
Nat Commun; 2020 Oct; 11(1):5066. PubMed ID: 33033255
[TBL] [Abstract][Full Text] [Related]
2. Structural basis of inducible costimulator ligand costimulatory function: determination of the cell surface oligomeric state and functional mapping of the receptor binding site of the protein.
Chattopadhyay K; Bhatia S; Fiser A; Almo SC; Nathenson SG
J Immunol; 2006 Sep; 177(6):3920-9. PubMed ID: 16951355
[TBL] [Abstract][Full Text] [Related]
3. CTLA4-Ig-Based Bifunctional Costimulation Inhibitor Blocks CD28 and ICOS Signaling to Prevent T Cell Priming and Effector Function.
Goenka R; Xu Z; Samayoa J; Banach D; Beam C; Bose S; Dooner G; Forsyth CM; Lu X; Medina L; Sadhukhan R; Sielaff B; Sousa S; Tao Q; Touw D; Wu F; Kingsbury GA; Akamatsu Y
J Immunol; 2021 Mar; 206(5):1102-1113. PubMed ID: 33495237
[TBL] [Abstract][Full Text] [Related]
4. Ligand binding sites of inducible costimulator and high avidity mutants with improved function.
Wang S; Zhu G; Tamada K; Chen L; Bajorath J
J Exp Med; 2002 Apr; 195(8):1033-41. PubMed ID: 11956294
[TBL] [Abstract][Full Text] [Related]
5. A signaling-enhanced chimeric receptor to activate the ICOS pathway in T cells.
Vettermann C; Victor HP; Sun Y; Plewa C; Gupta S
J Immunol Methods; 2015 Sep; 424():14-9. PubMed ID: 25956037
[TBL] [Abstract][Full Text] [Related]
6. ICOS-L as a Potential Therapeutic Target for Cancer Immunotherapy.
Marinelli O; Nabissi M; Morelli MB; Torquati L; Amantini C; Santoni G
Curr Protein Pept Sci; 2018; 19(11):1107-1113. PubMed ID: 29879883
[TBL] [Abstract][Full Text] [Related]
7. Targeting of inducible costimulator (ICOS) expressed on alloreactive T cells down-regulates graft-versus-host disease (GVHD) and facilitates engraftment of allogeneic bone marrow (BM).
Taylor PA; Panoskaltsis-Mortari A; Freeman GJ; Sharpe AH; Noelle RJ; Rudensky AY; Mak TW; Serody JS; Blazar BR
Blood; 2005 Apr; 105(8):3372-80. PubMed ID: 15618467
[TBL] [Abstract][Full Text] [Related]
8. The rationale behind targeting the ICOS-ICOS ligand costimulatory pathway in cancer immunotherapy.
Solinas C; Gu-Trantien C; Willard-Gallo K
ESMO Open; 2020 Jan; 5(1):. PubMed ID: 32516116
[TBL] [Abstract][Full Text] [Related]
9. Comparable in vivo efficacy of CD28/B7, ICOS/GL50, and ICOS/GL50B costimulatory pathways in murine tumor models: IFNgamma-dependent enhancement of CTL priming, effector functions, and tumor specific memory CTL.
Zuberek K; Ling V; Wu P; Ma HL; Leonard JP; Collins M; Dunussi-Joannopoulos K
Cell Immunol; 2003 Sep; 225(1):53-63. PubMed ID: 14643304
[TBL] [Abstract][Full Text] [Related]
10. Inducible Co-Stimulator (ICOS) in transplantation: A review.
Hodgson R; Christiansen D; Ierino F; Sandrin M
Transplant Rev (Orlando); 2022 Dec; 36(4):100713. PubMed ID: 35878486
[TBL] [Abstract][Full Text] [Related]
11. Characterization of a new human B7-related protein: B7RP-1 is the ligand to the co-stimulatory protein ICOS.
Yoshinaga SK; Zhang M; Pistillo J; Horan T; Khare SD; Miner K; Sonnenberg M; Boone T; Brankow D; Dai T; Delaney J; Han H; Hui A; Kohno T; Manoukian R; Whoriskey JS; Coccia MA
Int Immunol; 2000 Oct; 12(10):1439-47. PubMed ID: 11007762
[TBL] [Abstract][Full Text] [Related]
12. The landscape of
de Vos L; Grünwald I; Bawden EG; Dietrich J; Scheckenbach K; Wiek C; Zarbl R; Bootz F; Landsberg J; Dietrich D
Epigenetics; 2020 Nov; 15(11):1195-1212. PubMed ID: 32281488
[TBL] [Abstract][Full Text] [Related]
13. Characterization of human inducible costimulator ligand expression and function.
Aicher A; Hayden-Ledbetter M; Brady WA; Pezzutto A; Richter G; Magaletti D; Buckwalter S; Ledbetter JA; Clark EA
J Immunol; 2000 May; 164(9):4689-96. PubMed ID: 10779774
[TBL] [Abstract][Full Text] [Related]
14. Inducible T-cell co-stimulator (ICOS) and ICOS ligand are novel players in the multiple-myeloma microenvironment.
Boggio E; Gigliotti CL; Moia R; Scotta A; Crespi I; Boggione P; De Paoli L; Deambrogi C; Garzaro M; Vidali M; Chiocchetti A; Stoppa I; Rolla R; Dianzani C; Monge C; Clemente N; Gaidano G; Dianzani U
Br J Haematol; 2022 Mar; 196(6):1369-1380. PubMed ID: 34954822
[TBL] [Abstract][Full Text] [Related]
15. Inducible costimulatory molecule-B7-related protein 1 interactions are important for the clonal expansion and B cell helper functions of naive, Th1, and Th2 T cells.
Smith KM; Brewer JM; Webb P; Coyle AJ; Gutierrez-Ramos C; Garside P
J Immunol; 2003 Mar; 170(5):2310-5. PubMed ID: 12594252
[TBL] [Abstract][Full Text] [Related]
16. Differential expression of inducible costimulator-ligand splice variants: lymphoid regulation of mouse GL50-B and human GL50 molecules.
Ling V; Wu PW; Miyashiro JS; Marusic S; Finnerty HF; Collins M
J Immunol; 2001 Jun; 166(12):7300-8. PubMed ID: 11390480
[TBL] [Abstract][Full Text] [Related]
17. The CD28 related molecule ICOS: T cell modulation in the presence and absence of B7.1/2 and regulational expression in multiple sclerosis.
Wiendl H; Neuhaus O; Mehling M; Wintterle S; Schreiner B; Mitsdoerffer M; Wienhold W; Weissert R; Wessels J; Hartung HP; Weller M; Tolosa E; Melms A
J Neuroimmunol; 2003 Jul; 140(1-2):177-87. PubMed ID: 12864987
[TBL] [Abstract][Full Text] [Related]
18. Targeting the ICOS/ICOS-L pathway in a mouse model of established allergic asthma disrupts T follicular helper cell responses and ameliorates disease.
Uwadiae FI; Pyle CJ; Walker SA; Lloyd CM; Harker JA
Allergy; 2019 Apr; 74(4):650-662. PubMed ID: 30220084
[TBL] [Abstract][Full Text] [Related]
19. ICOS-ligand expression on plasmacytoid dendritic cells supports breast cancer progression by promoting the accumulation of immunosuppressive CD4+ T cells.
Faget J; Bendriss-Vermare N; Gobert M; Durand I; Olive D; Biota C; Bachelot T; Treilleux I; Goddard-Leon S; Lavergne E; Chabaud S; Blay JY; Caux C; Ménétrier-Caux C
Cancer Res; 2012 Dec; 72(23):6130-41. PubMed ID: 23026134
[TBL] [Abstract][Full Text] [Related]
20. Role of Inducible Co-Stimulator (ICOS) in cancer immunotherapy.
Amatore F; Gorvel L; Olive D
Expert Opin Biol Ther; 2020 Feb; 20(2):141-150. PubMed ID: 31738626
[No Abstract] [Full Text] [Related]
[Next] [New Search]
